CEAS
MCID: CHR603
MIFTS: 25

Chronic Enteropathy Associated with Slco2a1 Gene (CEAS)

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Chronic Enteropathy Associated with Slco2a1 Gene

MalaCards integrated aliases for Chronic Enteropathy Associated with Slco2a1 Gene:

Name: Chronic Enteropathy Associated with Slco2a1 Gene 58
Ceas 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Orphanet 58 ORPHA468641

Summaries for Chronic Enteropathy Associated with Slco2a1 Gene

MalaCards based summary : Chronic Enteropathy Associated with Slco2a1 Gene, also known as ceas, is related to crohn's disease and myelofibrosis. An important gene associated with Chronic Enteropathy Associated with Slco2a1 Gene is SLCO2A1 (Solute Carrier Organic Anion Transporter Family Member 2A1). The drugs Dexmedetomidine and Propofol have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and small intestine.

Wikipedia : 73 Chronic enteropathy associated with SLCO2A1 gene is a rare autosomal recessive enteropathy that was... more...

Related Diseases for Chronic Enteropathy Associated with Slco2a1 Gene

Diseases related to Chronic Enteropathy Associated with Slco2a1 Gene via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 crohn's disease 10.5
2 myelofibrosis 10.4
3 inflammatory bowel disease 10.4
4 primary hypertrophic osteoarthropathy 10.4
5 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2
6 colitis 10.2
7 hypokalemia 10.2
8 gastrointestinal system disease 10.2
9 cryptogenic multifocal ulcerous stenosing enteritis 10.2
10 refractory anemia 10.2
11 thyroid carcinoma 9.9

Graphical network of the top 20 diseases related to Chronic Enteropathy Associated with Slco2a1 Gene:



Diseases related to Chronic Enteropathy Associated with Slco2a1 Gene

Symptoms & Phenotypes for Chronic Enteropathy Associated with Slco2a1 Gene

Drugs & Therapeutics for Chronic Enteropathy Associated with Slco2a1 Gene

Drugs for Chronic Enteropathy Associated with Slco2a1 Gene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Evolocumab Approved Phase 4 1256937-27-5
7
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Amlodipine Approved Phase 4 88150-42-9 2162
10
Losartan Approved Phase 4 114798-26-4 3961
11
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
14 Antioxidants Phase 4
15 Neurotransmitter Agents Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Hypnotics and Sedatives Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Epinephryl borate Phase 4
21 Chlorhexidine gluconate Phase 4
22 Anesthetics, Local Phase 4
23 Hormones Phase 4
24 Antirheumatic Agents Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Cyclooxygenase Inhibitors Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Analgesics Phase 4
30 Antimetabolites Phase 4
31 Calcium, Dietary Phase 4
32 Anticholesteremic Agents Phase 4
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
34 Vasodilator Agents Phase 4
35 Hypolipidemic Agents Phase 4
36 Lipid Regulating Agents Phase 4
37 Fibrinolytic Agents Phase 4
38 Anti-Arrhythmia Agents Phase 4
39 Giapreza Phase 4
40 Angiotensinogen Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Angiotensin Receptor Antagonists Phase 4
43 Antihypertensive Agents Phase 4
44 Angiotensin II Type 1 Receptor Blockers Phase 4
45 Antipyretics Phase 4
46 calcium channel blockers Phase 4
47
Calcium Nutraceutical Phase 4 7440-70-2 271
48
tannic acid Approved Phase 3 1401-55-4
49
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
50
Simvastatin Approved Phase 3 79902-63-9 54454

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 The Protective Effect of Melatonin in Patients Under Carotid Endarterectomy Completed NCT03115034 Phase 4 Melatonin;placebo
2 Efficacy of Patient Controlled Epidural Anesthesia (PCEA) Versus Continuous Epidural Analgesia (CEA) for Post-thoracotomy Pain. Completed NCT01560429 Phase 4
3 Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA) With Intraoperative SSEP and MEP Monitoring: A Single-centre Prospective Randomized Controlled Trial Completed NCT04662177 Phase 4 Dexmedetomidine
4 A Carotid Stenting Boston Scientific Surveillance Program Carotid WALLSTENT Monorail Endoprosthesis FilterWire EZ™ Embolic Protection System Completed NCT00741091 Phase 4
5 Study of Lipids Inside the Carotid With Evolocumab: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy (SLICE-CEA CardioLink-8 Study) Recruiting NCT04539223 Phase 4 Evolocumab
6 Protocol for a Single Center Randomized Controlled Trial of Liposomal Bupivacaine Intercostal Nerve Blockade Versus Continuous Thoracic Epidural for Regional Analgesia in Patients With Multiple Rib Fractures Recruiting NCT03574376 Phase 4 Bupivacaine Liposome Injection;Bupivacaine
7 Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis Terminated NCT00805311 Phase 4 atorvastatin, aspirin, losartan, amlodipine
8 Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases; the COLOPEC-II Randomized Multicentre Trial Recruiting NCT03413254 Phase 3
9 Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer Recruiting NCT03659448 Phase 3 SGM-101
10 Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery Recruiting NCT04642924 Phase 2, Phase 3 SGM-101
11 Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes Recruiting NCT02850081 Phase 3 Statin;Atorvastatin
12 Follow-Up of Fully Resected Stage II or III Colorectal Cancer. Phase III Multicentric Prospective Randomised Study Active, not recruiting NCT00995202 Phase 3
13 Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Colon Cancer at High Risk of Peritoneal Carcinomatosis Active, not recruiting NCT02231086 Phase 3 Standard adjuvant systemic chemotherapy
14 A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma Not yet recruiting NCT04037241 Phase 2, Phase 3 gemcitabine/nab paclitaxel;NLIR+FU/FA;Capecitabine
15 A Phase I/II Clinical Study of Immunotherapy for Advanced Colorectal Cancers Using CEA-Pulsed Dendritic Cells Mixed With Tetanus Toxoid and Subsequent IL-2 Treatment Unknown status NCT00154713 Phase 1, Phase 2
16 Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
17 Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer : A Multicentric Phase I/II Study of Fractionated TF2 Plus 90Y-IMP288 (RITCOLON) Unknown status NCT02300922 Phase 1, Phase 2 Antibody TF2;90-Y-IMP-288;111-In-IMP-288
18 A Single-arm Pilot Clinical Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy Unknown status NCT02959151 Phase 1, Phase 2 CAR-T cell
19 Open-label, Single Center, Phase Ⅱ Clinical Trial to Evaluate Safety and Efficacy of Immuncell-LC in the Patients for Refractory Metastatic Colorectal Cancer Unknown status NCT03220984 Phase 2
20 Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic Completed NCT00499083 Phase 2 aromatase inhibition therapy;cyclophosphamide;doxorubicin hydrochloride;paclitaxel;tamoxifen citrate
21 Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC) Completed NCT01221675 Phase 1, Phase 2 Antibody TF2
22 A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 and GM-CSF in Patients With CEA Expressing Tumors Completed NCT00003125 Phase 2
23 A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
24 A Randomized Pilot Phase II Study of Immunization With Modified CEA (CAP1-6D) Peptide In Patients With Locally Advanced Or Surgically Resected Adenocarcinoma of the Pancreas Completed NCT00203892 Phase 1, Phase 2
25 Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA Completed NCT01730612 Phase 1, Phase 2 TF2 - 68 Ga-IMP-288:
26 A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA Completed NCT01147965 Phase 1, Phase 2
27 A Phase I/II Study of Active Immunotherapy With CEA(6D)VRP Vaccine(AVX701)in Patients With Advanced or Metastatic Malignancies Expressing CEA or Stage III Colon Cancer Completed NCT00529984 Phase 1, Phase 2
28 Induction of Specific T Cell Responses in Colorectal Cancer Patients With Liver Metastases Upon Vaccination With Autologous Dendritic Cells Pulsed With CEA-peptide or Electroporated With CEA-RNA: Evaluation of in Vivo Immune Response. Completed NCT00228189 Phase 1, Phase 2
29 Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities Completed NCT00001568 Phase 2 2-Fluoro-2-deoxyglucose
30 Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Completed NCT03127098 Phase 1, Phase 2
31 A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) Completed NCT00804843 Phase 2 Atorvastatin/niacin extended-release;Atorvastatin;Simvastatin;Simvastatin
32 Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma. Completed NCT01730638 Phase 1, Phase 2 • TF2 and 68 Ga-IMP-288
33 Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin Completed NCT00004048 Phase 1, Phase 2 doxorubicin hydrochloride
34 Phase I/II Trial of High-Dose Radioimmunotherapy With a 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody for the Treatment of Stage IV Breast Cancer Completed NCT00004085 Phase 1, Phase 2
35 A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG Completed NCT02015104 Phase 2
36 Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer Recruiting NCT04348643 Phase 1, Phase 2
37 Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Patients With Resectable or Locally Advanced Gastric or Gastro-oesophageal Junction Cancer Recruiting NCT03957564 Phase 2 Neoadjuvant chemotherapy with PSOX regimen.
38 QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy Active, not recruiting NCT03387111 Phase 1, Phase 2 Aldoxorubicin HCl;Avelumab;bevacizumab;Capecitabine;Cetuximab;Cisplatin;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel;Necitumumab
39 NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy Active, not recruiting NCT03563157 Phase 1, Phase 2 Avelumab;Capecitabine;Cetuximab;Cyclophosphamide;5-Fluorouracil;Leucovorin;Nab-paclitaxel;Oxaliplatin;Regorafenib
40 NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting NCT03387085 Phase 1, Phase 2 Aldoxorubicin HCl;Capecitabine;Cisplatin;Cyclophosphamide;5-Fluorouracil;Leucovorin;nab-Paclitaxel
41 QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy Active, not recruiting NCT03586869 Phase 1, Phase 2 Aldoxorubicin HCl;Capecitabine;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel;Oxaliplatin
42 A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer Active, not recruiting NCT01856920 Phase 2
43 A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic or Unresectable Colorectal Cancer Active, not recruiting NCT03050814 Phase 2 Avelumab;Bevacizumab;5-FU;Leucovorin;Oxaliplatin;Capecitabine;5-FU
44 NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting NCT03387098 Phase 1, Phase 2 Aldoxorubicin HCl;Capecitabine;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel;lovaza;Oxaliplatin
45 NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adaptive T-cell Therapy (Adenovirus, Yeast, Fusion Protein Vaccine) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting NCT03329248 Phase 1, Phase 2 Capecitabine;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel;lovaza;Oxaliplatin
46 NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting NCT03136406 Phase 1, Phase 2 Cyclophosphamide;Oxaliplatin;Capecitabine;5-Fluorouracil;Leucovorin;nab-paclitaxel
47 "Phase II/Pilot Study of 2nd Generation Anti-CEA Esigner T Cells in Adenocarcinomas" Suspended NCT01723306 Phase 2
48 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
49 A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion Terminated NCT00048893 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;paclitaxel;Mesna
50 A Phase 2 Study of Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma Terminated NCT01333124 Phase 2

Search NIH Clinical Center for Chronic Enteropathy Associated with Slco2a1 Gene

Genetic Tests for Chronic Enteropathy Associated with Slco2a1 Gene

Anatomical Context for Chronic Enteropathy Associated with Slco2a1 Gene

MalaCards organs/tissues related to Chronic Enteropathy Associated with Slco2a1 Gene:

40
Liver, T Cells, Small Intestine, Colon, Pancreas, Thyroid, Lung

Publications for Chronic Enteropathy Associated with Slco2a1 Gene

Articles related to Chronic Enteropathy Associated with Slco2a1 Gene:

(show top 50) (show all 996)
# Title Authors PMID Year
1
Treatment of giant congenital melanocytic nevi with cultured epithelial autografts: Clinical and histopathological analysis. 61
33778134 2021
2
Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. 61
33451278 2021
3
Selection for high levels of resistance to double-stranded RNA (dsRNA) in Colorado potato beetle (Leptinotarsa decemlineata Say) using non-transgenic foliar delivery. 61
33753776 2021
4
Short term response of plankton community to nutrient enrichment in central eastern Arabian Sea: Elucidation through mesocosm experiments. 61
33773214 2021
5
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer. 61
33645243 2021
6
A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults. 61
33641765 2021
7
Long-term stroke risk with carotid endarterectomy in patients with severe carotid stenosis. 61
32707387 2021
8
Effect of triclosan on the pathogenesis of allergic diseases among children. 61
33654271 2021
9
Contemporary Trends in Physician Utilization Rates of CEA and CAS for Asymptomatic Carotid Stenosis among Medicare Beneficiaries. 61
32890650 2021
10
Weekend Carotid Endarterectomies are Not Associated with a Greater Risk of Stroke and/or Death in Australia and New Zealand. 61
32800885 2021
11
Estimated Prevalence of Cronkhite-Canada Syndrome, Chronic Enteropathy Associated With SLCO2A1 Gene, and Intestinal Behçet's Disease in Japan in 2017: A Nationwide Survey. 61
32092751 2021
12
Patches of different types for carotid patch angioplasty. 61
33598915 2021
13
Longitudinal Survey of Trainee Case Log Entry for Carotid Endarterectomy: Trends in Neurologic, General, and Vascular Surgery. 61
33144210 2021
14
Mini-Skin Incision for Carotid Endarterectomy: Neurological Morbidity and Health-related Quality of Life. 61
32768532 2021
15
Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review. 61
33593223 2021
16
Centriole length control. 61
33220554 2021
17
Comparison of Single and Dual Monitoring during Carotid Endarterectomy. 61
33390558 2021
18
[Current place of cultured epithelial autografts in the management of massive burns and future prospects: Literature review]. 61
33380355 2021
19
Impact of Chronic Kidney Disease Under Nephrology Care on Outcomes of Carotid Endarterectomy. 61
33632608 2021
20
Cost effectiveness analyses of total hip arthroplasty for hip osteoarthritis: A PRISMA systematic review. 61
33128841 2021
21
A review of the combined effects of climate change and other local human stressors on the marine environment. 61
33035971 2021
22
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence. 61
33472442 2021
23
Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. 61
33431159 2021
24
Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction? 61
33431158 2021
25
Integrating Alternative Social Value Judgments Into Cost-Effectiveness Analysis of Vaccines: An Application to Varicella-Zoster Virus Vaccination. 61
33431152 2021
26
Early and Long-Term Outcomes of Carotid Stenting and Carotid Endarterectomy in Women. 61
33763447 2021
27
Frequency and Significance of Maneuvers to Dissect the Distal Internal Carotid Artery During Carotid Endarterectomy. 61
33455523 2021
28
Long-term Results With CorMatrix ECM Patches After Carotid Endarterectomy. 61
33530005 2021
29
Current Orthopaedic Health Economic Literature: Quality Is High but Ethical and Societal Perspectives Are Lacking. 61
33515733 2021
30
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review. 61
33431148 2021
31
Practice patterns in the use of completion imaging after carotid endarterectomy. 61
32623109 2021
32
The benefit of deferred carotid revascularization in patients with moderate-severe disabling cerebral ischemic stroke. 61
32348801 2021
33
[Clinical and genetic characteristics of patients with chronic enteropathy associated with SLCO2A1 gene]. 61
33397021 2021
34
A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer. 61
33469803 2021
35
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action. 61
33465398 2021
36
Regional Anesthesia is Underutilized for Carotid Endarterectomy Despite Improved Perioperative Outcomes Compared with General Anesthesia. 61
33373769 2020
37
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. 61
32166657 2020
38
A systematic review of the budget impact analyses for antitumor drugs of lung cancer. 61
33292288 2020
39
The ABCs of CEAs: Building Blocks for Decision Making. 61
33255107 2020
40
Safety and efficacy of basic fibroblast growth factors for deep second-degree burn patients. 61
33054995 2020
41
An algorithm to generate correlated input-parameters to be used in probabilistic sensitivity analyses. 61
33403091 2020
42
Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making? 61
31881441 2020
43
Epiglottic hematoma after carotid endarterectomy with cervical block. 61
33134635 2020
44
Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. 61
33025257 2020
45
The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review. 61
33238605 2020
46
Modelling the cost-effectiveness of total knee arthroplasty: A systematic review. 61
33093759 2020
47
Contextualising video game engagement and addiction in mental health: the mediating roles of coping and social support. 61
33235930 2020
48
Cultured Epithelial Autograft Combined with Micropatterned Dermal Template Forms Rete Ridges In Vivo. 61
32486917 2020
49
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. 61
32794041 2020
50
Adverse cardiac events after vascular surgery are prevalent despite negative results of preoperative stress testing. 61
32247699 2020

Variations for Chronic Enteropathy Associated with Slco2a1 Gene

Expression for Chronic Enteropathy Associated with Slco2a1 Gene

Search GEO for disease gene expression data for Chronic Enteropathy Associated with Slco2a1 Gene.

Pathways for Chronic Enteropathy Associated with Slco2a1 Gene

GO Terms for Chronic Enteropathy Associated with Slco2a1 Gene

Sources for Chronic Enteropathy Associated with Slco2a1 Gene

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....